-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

233 Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III
Hematology Disease Topics & Pathways:
clinical trials, Research, Lymphomas, non-Hodgkin lymphoma, Clinical Research, Diseases, Lymphoid Malignancies
Saturday, December 10, 2022: 3:00 PM

Catherine Thieblemont, MD, PhD1, Javier Munoz2*, Alessandra Tucci, MD3*, Carlo Visco, MD4*, Guillaume Cartron, MD, PhD5*, Paolo Corradini6, Ian W. Flinn, MD PhD7, Thomas Gastinne, MD8*, Kamal Krimo Bouabdallah,9*, Luca Arcaini10*, Grzegorz S. Nowakowski, MD11, Louise Roulin12*, Max Topp13*, Shekeab Jauhari, MD14*, Vladan Vucinic, MD15*, Peter Martin, FRCPC, MD, MS16, Argyrios Gkasiamis, MD17, James Drew18*, Parth Rao18*, Mark Kaplan18*, Yiming Cheng18*, Ju Li, PhD18* and Franck Morschhauser, MD, PhD19*

1Hôpital Saint-Louis, Paris, France
2Mayo Clinic, Phoenix, AZ
3Spedali Civili di Brescia, Brescia, Italy
4University of Verona, Verona, Italy
5CHU de Montpellier – Hôpital Saint-Eloi, Montpellier, France
6Istituto Nazionale dei Tumori, Milan, Italy
7Sarah Cannon Research Institute, Nashville, TN
8Centre Hospitalier Universitaire de Nantes, Nantes, France
9Hôpital Haut Leveque, Gironde, France
10Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
11Mayo Clinic, Rochester, MN
12Hôpital Henri Mondor, Creteil, France
13Universitӓtsklinikum Würzburg, Würzburg, Germany
14Florida Cancer Specialists and Research Institute, Sarah Cannon Research Institute, Lake Mary, FL
15Universitӓtsklinikum Leipzig, Leipzig, Germany
16Weill Cornell Medicine, New York, NY
17Bristol Myers Squibb, Boudry, Switzerland
18Bristol Myers Squibb, Princeton, NJ
19Centre Hospitalier Régional Universitaire de Lille, Lille, France

Introduction

Iberdomide (IBER; CC-220) is an oral cereblon E3 ligase modulator (CELMoD) agent that causes degradation of Ikaros and Aiolos, transcription factors essential for lymphoma cell survival. In vitro studies suggest IBER enhances T-cell immunostimulatory and direct cytotoxic effects versus lenalidomide. IBER demonstrated apoptotic activity in diffuse large B-cell lymphoma (DLBCL) cell lines independent of cell of origin (COO). We present data from an ongoing phase 1/2 open-label study (NCT04464798) assessing safety, pharmacokinetics (PK), and preliminary efficacy of IBER alone or in combination with an anti-CD20 monoclonal antibody (mAb) in patients (pts) with relapsed or refractory (RR) lymphomas.

Methods

Pts with RR lymphomas and ≥ 2 prior lines of treatment (tx) were given escalating doses of IBER alone (cohort A: all lymphomas), or with rituximab (cohort B: all B-cell lymphomas) or obinutuzumab (cohort C: marginal zone lymphoma [MZL] or grade 1–3a follicular lymphoma [FL]) to determine maximum tolerated dose (MTD). IBER starting dose was 1 mg daily (days 121 every 28 days) with sequential escalation to 1.3 mg and 1.6 mg. Pts received IBER for ≤ 24 cycles (12 for MZL/FL) or until disease progression or unacceptable toxicity. Pts in cohorts B and C received rituximab or obinutuzumab, respectively, for ≤ 6 cycles. Granulocyte-colony stimulating factor (G-CSF) was permitted after the dose limiting toxicity (DLT) evaluation period (tx cycle 1) was completed. Pts with measurable disease at baseline and a subsequent scan (after ≤ 3 months of tx based on clinical assessment) for response were response evaluable. The primary endpoint was MTD. Secondary endpoints included safety, PK characterization, overall response rate (ORR), and complete remission (CR) rate. Biomarker assessments were exploratory endpoints.

Results

Of the 46 pts enrolled at data cutoff (March 31, 2022), 18 had RR DLBCL (cohort A, n = 8; cohort B, n = 10) and 10 had RR FL (cohort A, n = 2; cohort C, n = 8). Pts were 73% male with a median age of 69 years. Most (76%) had stage III/IV disease, while 85% had an ECOG performance status of 0–1. Median (range) prior lines of tx was 4 (1–12).

The primary reasons for tx discontinuation (49%) were progressive disease or death. Relative IBER dose intensity per cycle was maintained at 92%. No cohort achieved MTD.

Tx-emergent adverse events (TEAEs) in ≥ 10% of pts included neutropenia, anemia, thrombocytopenia, and constipation (Table 1). Grade 3–4 TEAEs were primarily hematologic: neutropenia (49%), anemia (15%), and thrombocytopenia (13%). Febrile neutropenia occurred in 4% of pts, as did sepsis. In cohorts A and B, 1 (grade 4 thrombocytopenia) and 2 (both grade 4 neutropenia) DLTs occurred, respectively. In cohort C, 4 DLTs occurred: grade 4 neutropenia (n = 2), grade 3 facial edema (n = 1), and grade 3 hypercalcemia (n = 1). No grade 5 TEAEs occurred.

ORR in response-evaluable pts (n = 38) was 55%; 32% achieved CR (Table 2). In the 7 cohort B pts with RR DLBCL (median: 5 prior tx lines), ORR was 71%; 29% achieved CR. In cohort C (n = 13; MZL, n = 5; FL, n = 8), the ORR was 69%; CR rate was 39%. ORR and CR were independent of COO and were achieved in pts with prior exposure to lenalidomide and chimeric antigen receptor (CAR) T cell tx.

IBER was absorbed rapidly (median Tmax, 2.54.0 hours) and PK exposure (Cmax and area under curve) at steady state increased in a dose-related manner across the tested dose range. Consistent with preclinical data, higher doses increased Ikaros degradation in B cells (37% at 1.0 mg, 60% at 1.3 mg) but not in T cells (64% at 1.0 mg, 66% at 1.3 mg), at 6 hours post-dose. Peripheral immunophenotyping at C1D15 indicated IBER increased 2–3-fold the numbers of proliferating CD4+ T cells and activated natural killer cells. Naive T cells decreased 2-fold. Preliminary PK/pharmacodynamic analyses suggested a dose-response trend, with higher exposure related to greater reduction of Ikaros/Aiolos.

Conclusions

IBER alone and in combination with anti-CD20 mAbs showed promising activity in pts with RR lymphoma. CELMoD agent-associated neutropenia was a predictable on-target toxicity manageable with G-CSF use and did not appear to increase risk of febrile neutropenia or infections. These data highlight the potential of CELMoD agent-based tx in pts with RR lymphoma to address unmet needs such as treating disease progression after CAR T cell tx.

Study support: This study was funded by Bristol Myers Squibb.

Disclosures: Thieblemont: Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel Support; Incyte: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Other: Travel Support; Celgene: Consultancy, Honoraria, Other: Travel Support; Novartis: Consultancy, Honoraria, Other: Travel Support, Research Funding; AbbVie: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Other: Travel Support; Bristol Myers Squibb: Consultancy, Honoraria, Other: Travel Support. Munoz: Pharmacyclics/Abbvie, Bayer, Gilead/Kite Pharma, Pfizer, Janssen, Juno/Celgene, Bristol Myers Squibb, Kyowa, Alexion, Fosunkite, Innovent, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, Beigene, Servier, Novartis, Morphosys/I: Consultancy; Bayer, Gilead/Kite Pharma, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium: Research Funding; Targeted Oncology, OncView, Curio, Kyowa, Physicians' Education Resource, and Seattle Genetics: Honoraria; Gilead/Kite Pharma, Kyowa, Bayer, Pharmacyclics/Janssen, Seattle Genetics, Acrotech/Aurobindo, Beigene, Verastem, AstraZeneca, Celgene/Bristol Myers Squibb, Genentech/Roche: Speakers Bureau. Tucci: Sanofi: Membership on an entity's Board of Directors or advisory committees; Kiowa Kyrin: Honoraria; Gentili: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; MSD: Honoraria; Takeda: Honoraria. Cartron: Gilead, Novartis, Mylteni, Sanofi, Abbvie, Takeda, Roche, Janssen, Celgene, Novartis, Bristol Myers Squibb: Honoraria; MabQi, Ownards Therapeutics, Abbvie, Roche, Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees. Corradini: Abbvie, ADC Therapeutics, Amgen, BeiGene, Celgene, Daiichi Sankyo, Gilead/Kite, GlaxoSmithKline, Incyte, Janssen, KyowaKirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda: Other: Data monitoring board or advisory board; Abbvie, Amgen, Bristol Myers Squibb, Celgene, Gilead/Kite, Janssen, Novartis, Roche, Takeda: Other: Support for attending meetings or travel; AbbVie, ADC Therapeutics, Amgen, BeiGene, Celgene, Daiichi Sankyo, Gilead/Kite, GlaxoSmithKline, Incyte, Janssen, KyowaKirin, Nerviano, Novartis, Roche, Sanofi, Takeda: Honoraria; Abbvie, ADC Therapeutics, Amgen, BeiGene, Celgene, Daiichi Sankyo, Gilead/Kite, GlaxoSmithKline, Incyte, Janssen, KyowaKirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda: Consultancy. Flinn: CTI Biopharma: Research Funding; Incyte: Research Funding; Forty Seven: Research Funding; Genmab: Consultancy; Acerta Pharma: Research Funding; Kite Pharma: Consultancy, Research Funding; Iksuda Therapeutics: Consultancy; Unum Therapeutics: Research Funding; TG Therapeutics: Consultancy, Research Funding; Fate Therapeutics: Research Funding; Portola Pharmaceuticals: Research Funding; TCR2 Therapeutics: Research Funding; Millenium Pharmaceuticals: Research Funding; Rhizen Pharmaceuticals: Research Funding; Epizyme: Research Funding; City of Hope National Medical Center: Research Funding; Verastem: Consultancy, Research Funding; MorphoSys: Consultancy, Research Funding; ArQule: Research Funding; Constellation Pharmaceuticals: Research Funding; Hutchison MediPharma: Consultancy; Nurix Therapeutics: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Roche: Consultancy, Research Funding; Bristol Myers Squibb: Research Funding; Celgene: Research Funding; Agios: Research Funding; IGM Biosciences: Research Funding; Genentech: Consultancy, Research Funding; Gilead Sciences: Research Funding; CALIBR: Research Funding; CALGB: Research Funding; Novartis: Consultancy, Research Funding; Seattle Genetics: Research Funding; Servier Pharmaceuticals: Consultancy; Takeda: Consultancy; Janssen: Consultancy, Research Funding; InnoCare Pharma: Consultancy, Research Funding; Pfizer: Research Funding; Vincerx Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Curis: Research Funding; Forma Therapeutics: Research Funding; Infinity Pharmaceuticals: Research Funding; Loxo@Lilly: Research Funding; Merck: Research Funding; Tessa Therapeutics: Research Funding; Triphase Research & Development Corp: Research Funding; 2seventy bio: Research Funding; Century Therapeutics: Consultancy; Biopath: Research Funding; Myeloid Therapeutics: Research Funding; Trillium Therapeutics: Research Funding; Secura Bio: Consultancy; Xencor: Consultancy; BeiGene: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding. Gastinne: Gilead/Kite, Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings/travel, participation in a data safety monitoring board or advisory board. Arcaini: ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees; Celgene/Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; EUSA Pharma: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead Sciences: Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees; Verastem: Membership on an entity's Board of Directors or advisory committees. Nowakowski: MorphoSys US Inc: Consultancy, Other: Grants and nonfinancial support; Kymera Therapeutics: Consultancy, Other: Other support; Kite Pharma Inc.: Consultancy, Other: Other support; Karyopharm: Consultancy, Other: Other support; Incyte: Consultancy, Other: Other support; Genentech, Inc: Consultancy, Research Funding; F. Hoffmann-La Roche Ltd: Consultancy, Research Funding; Daiichi Sankyo Inc: Consultancy, Other: Other support; Curis, Inc.: Consultancy; Celgene Corporation/Bristol Myers Squibb: Consultancy, Research Funding; Blueprint Medicines Corporation: Consultancy, Other: Other support; Bantam Pharmaceutical: Consultancy; NanoString: Research Funding; Ryvu Therapeutics: Consultancy, Other: Other support; Selvita: Consultancy; TG Therapeutics: Consultancy, Other: Other support; Zai Lab: Consultancy, Other: Other support; Bristol Myers Squibb/Celgene: Other: Grants and other support ; Roche: Other: Grants and other support . Topp: Gilead, Roche, Regeneron: Consultancy; Amgen, Kite, Roche, MacroGenics, Regeron: Research Funding. Vucinic: Novartis, Gilead Kite, Takeda, MSD, BMS Celgene, Abbvie, Amgen: Honoraria; MSD, BMS Celgene, Novartis, Gilead Kite, Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sobi, BMS Celgene: Other: travel, accommodations, expenses. Martin: ADCT: Consultancy; AstraZeneca: Consultancy; Beigene: Consultancy; BMS: Consultancy; Daiichi Sankyo: Consultancy; Epizyme: Consultancy; Genentech: Consultancy; Janssen: Consultancy; Regeneron: Consultancy; Takeda: Consultancy. Gkasiamis: Bristol Myers Squibb: Current Employment. Drew: Bristol Myers Squibb: Current Employment. Rao: Bristol Myers Squibb: Current Employment. Kaplan: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Cheng: Bristol Myers Squibb: Current Employment. Li: Bristol Myers Squibb: Current Employment, Current holder of stock options in a privately-held company. Morschhauser: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead Sciences: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy; Genmab: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Allogene therapeutics: Membership on an entity's Board of Directors or advisory committees; Miltenyi: Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

*signifies non-member of ASH